Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1107-1114 , August 2010

Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation

  • David A. Rizzieri

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • Corresponding Author InformationCorrespondence and reprint requests: David A. Rizzieri, MD, Duke University Medical Center, Marrow and Stem Cell Transplantation Program, Box 3961, Durham NC 27705.
    • ,
  • Robert Storms

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Dong-Feng Chen

      Affiliations

    • Duke University Medical Center Department of Pathology, Durham, North Carolina
    • ,
  • Gwynn Long

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Yiping Yang

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Daniel A. Nikcevich

      Affiliations

    • St. Mary's-Duluth Clinical Cancer Center, Duluth, Minnesota
    • ,
  • Cristina Gasparetto

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Mitchell Horwitz

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • John Chute

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Keith Sullivan

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Therese Hennig

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Debashish Misra

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Christine Apple

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Megan Baker

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Ashley Morris

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Patrick G. Green

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina
    • ,
  • Vic Hasselblad

      Affiliations

    • Duke University Medical Center Department of Bioinfomatics and Biostatistics, Durham, North Carolina
    • ,
  • Nelson J. Chao

      Affiliations

    • Duke University Medical Center Department of Medicine, Division of Cellular Therapy, Durham, North Carloina

Received 12 November 2009 ,Accepted 18 February 2010.

References 

  1. Rizzieri DA, Long G, Vredenburgh J, et al. Successful allogeneic engraftment of mismatched unrelated cord blood following non-myeloablative conditioning. Blood. 2001;98:3486–3488
  2. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758
  3. Rizzieri DA, Koh LP, Long GD, et al. Clinical outcome and immune reconstitution following Alemtuzumab T cell depleted mismatched non-myeloablative allogoneic immunotherapy. J Clin Oncol. 2007;25:690–697
  4. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:1279–1287
  5. Falda M, Busca A, Baldi I, et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol. 2007;82:863–866
  6. Keil F, Kalhs P, Haas O, et al. Relapse of Philadelphia chromosome positive acute lymphoblastic leukemia after marrow transplantation: sustained molecular remission after early and dose-escalating infusion of donor leukocytes. Br J Haematol. 1997;97:161–164
  7. Drobyski W, Keever C, Roth M, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: effficacy and toxicity of a defined T cell dose. Blood. 1993;82:2310–2318
  8. Gurman G, Arslan O, Koc H, et al. Donor leukocyte infusion for relapsed ANLL after allogeneic BMT and the use of interferon alpha to induce graft versus leukemia effect. Bone Marrow Transplant. 1996;18:825–826
  9. Vago L, Perna S, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–488
  10. Ruggeri L, Cappani M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoetic transplants. Science. 2002;295:2097–2100
  11. Costello RT, Fauriat C, Sivori S, et al. NK cells: innate immunity against hematological malignancies?. Trends Immunol. 2004;25:328–333
  12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  13. http://ctep.cancer.gov/forms/ctcaev3to2.pdf
  14. FACT. Standards for Hematopoietic Progenitor Cell Collection, Processing, & Transplantation, 2nd ed. 2002.
  15. Rizzieri DA, Dev P, Long GD, et al. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. Bone Marrow Transplant. 2009;43:327–333
  16. Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma. 2005;46:1251–1260
  17. Morris EC, Rebello P, Thomson KJ, et al. Pk of alemtuzumab used in vivo and in vitro in allogeneic transplantation. Blood. 2003;102:404–406
  18. Ruggeri L, Cappani M, Cassuci M, et al. Role of natural killer cells alloreactivity in HLA-mismatched hematopoetic stem cell transplantation. Blood. 1999;94:333–339
  19. Zoller M. Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option?. Cancer Immunol Immunother. 2004;53:659–676
  20. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for hematopoetic transplants. Nat Rev. 2003;3:108–122
  21. Schulze A, Schirutschke H, Oelschlägel U, et al. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol. 2008;36:378–389
  22. Vago L, Forno B, Sormani M, et al. Temporal, quantitative, and functional characteristics of single KIR + alloreactive natural killer cell recovery account for impaired GVL activity after haploidentical hematopoietic stem cell transplantation. Blood. 2008;112:3488–3499
  23. Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006;12:6079–6086
  24. Ishikawa E, Tsuboi K, Saijo K, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004;24:1861–1871
  25. Shi J, Tricot G, Szmania S, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008;143:641–653
  26. Duwendag J, Huppert V, Alex R, et al. Optimized clinical scale selection of CD 56+CD3− natural killer cells for cellular immunotherapy. 20th International NK Cell Workshop, Noordwjkerhout, The Netherlands (Abstract), 2004.
  27. Wolf I, Duwendag J, Arendt A, et al. Isolation of CD56+ natural killer cells using the CliniMACS MARRS Tubing Set, a newly developed Tubing Set including a cross-flow filtration module for removal of unbound agent. Annual Meeting of American Society of Hematology, San Diego, California, USA (Abstract), 2004.
  28. Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181–187
  29. Lopez RD, Xu S, Guo B, et al. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood. 2000;96:3827–3837
  30. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113:4771–4779
  31. Krebs P, Barnes M, Lampe K, et al. NK cell-mediated killing of target cells triggers robust antigen-specific T cell mediated and humoral responses. Blood. 2009;113:6593–6602
  32. Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica. 2008;93:1852–1858
  33. Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and re-definition of inhibitory KIR specificity. Blood. 2009;113:3119–3129
  34. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433–440
  35. Cooper M, Fehniger T, Caligiuri M. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–640
  36. Caligiuri M. Human natural killer cells. Blood. 2008;112:461–469
  37. Prasad V, Chen D, Broadwater G, et al. Differential Impact of inhibitory and activating killer Ig-like receptors and HLA Ligand on outcomes of transplantation for myeloid and lymphoid malignancies. Blood. 2008;
  38. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113:726–732

 Financial disclosure: See Acknowledgments on page 1113.

 Current address for Patrick G. Green: Department of Medicine, University of Miami, Miami, FL.

PII: S1083-8791(10)00089-3

doi: 10.1016/j.bbmt.2010.02.018

Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1107-1114 , August 2010

Article Tools

* Image Usage & Resolution